Matrix metalloproteinase-3 joins a growing list of proteases that regulate vascular calcification.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

1. Decoding vascular calcification: mechanistic insights and translational strategies.Cellular and molecular life sciences : CMLS · 2026
   Review
2. SEPT9 methylation as a diagnostic and predictive biomarker in the progression of ductal carcinoma in situ to invasive breast cancer.Scientific reports · 2025
   Article
3. Gallic acid: a dietary metabolite's therapeutic potential in the management of atherosclerotic cardiovascular disease.Frontiers in pharmacology · 2024
   Review

Corrections and comments

• Comment on
  Smooth muscle cell-specific matrix metalloproteinase 3 deletion reduces osteogenic transformation and medial artery calcification.2024

Authors and funding

3 authors at 1 institution in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as